文献速递药物不良反应与药物警戒

阿扎胞苷治疗患者的心力衰竭:病例报告与Vigibase失衡分析

Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.
PubMed 文献 · Br J Clin Pharmacol · 2020-02-03

该研究评估吡啶类似物阿扎胞苷(AZA)暴露与心力衰竭(CF)的潜在关联。回顾性收集法国骨髓增生异常综合征协作组多中心AZA治疗患者的CF病例,并在Vigibase数据库中对CF报告进行失衡分析。4例病例报告均有心血管病史,1例再次暴露后CF复发;Vigibase中检索到307份AZA相关CF个体病例安全报告,SMQ心力衰竭的ROR为1.3,首选术语心力衰竭的ROR为5.1、急性心力衰竭的ROR为23.2。结论提示AZA可能参与CF发生,建议有心血管病史者用药前评估心脏并定期监测心功能。

要点

  • 有心血管病史者使用AZA前应评估心脏,治疗期间定期监测心功能。
  • Vigibase失衡分析显示AZA与心力衰竭报告存在显著失衡信号。
  • 1例患者再次使用AZA后心力衰竭复发,提示再暴露风险。

核心结论

  • 本研究提示AZA可能在心力衰竭发生中具有潜在作用。
  • 对有心血管病史的患者,建议AZA用药前进行心脏评估并在治疗期间定期监测心功能。

研究设计与样本

  • 回顾性收集法国骨髓增生异常综合征协作组多个中心接受AZA治疗患者的心力衰竭病例并进行描述分析。
  • 利用WHO全球个体病例安全报告数据库Vigibase进行失衡分析,按SMQ broad心力衰竭及首选术语心力衰竭、急性心力衰竭检索ICSRs。
  • 通过比较AZA作为可疑药物与同期数据库中其他可疑药物的相同不良反应报告比例,计算报告比值比(ROR)及其95%双侧置信区间。

主要发现

  • 4例病例报告中所有患者均有心血管病史。
  • 1例患者在再次使用AZA后心力衰竭复发。
  • Vigibase药物警戒分析检索到307份AZA相关心力衰竭ICSRs(SMQ)。
  • SMQ心力衰竭的ROR为1.3。
  • 首选术语心力衰竭的ROR为5.1,急性心力衰竭的ROR为23.2。

临床怎么用

  • 对有心血管病史的患者,AZA启动前应进行心脏评估。
  • AZA治疗期间应定期监测心脏功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF) and AZA exposure. METHODS: Cases of CF in patients treated with AZA were retrospectively collected and described from several centres of the Groupe Francophone des Myélodysplasies. A description analysis and a disproportionality analysis using Vigibase, the WHO Global Individual Case Safety Reports (ICSRs) database, were conducted on ICSRs by the Standardized MedDRA Queries (SMQ broad) cardiac failure and by preferred terms cardiac failure and cardiac failure acute. The reported odds ratio (ROR) and its 95% 2-sided confidence interval was computed by comparing the proportion of CF reports with the suspected drug (AZA) and the proportion of reports of the same adverse drug reaction with all other suspected drugs in the database during the same period. RESULTS: In the 4 case reports, all patients presented a cardiovascular history. In 1 patient, CF recurred after AZA re-challenge. The pharmacovigilance analysis in Vigibase retrieved 307 ICSRs of CF (SMQ) with AZA. Significant disproportionality signals associated with AZA were identified by using the SMQ cardiac failure (ROR 1.3) and the preferred terms cardiac failure (ROR 5.1) and cardiac failure acute (ROR 23.2). CONCLUSION: This study points to the potential role of AZA in the occurrence of CF. Cardiac evaluation before AZA initiation and regular monitoring of cardiac function during AZA treatment should be performed in patients with a history of cardiovascular disease.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Perino J, Mottal N, Bohbot Y, et al. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase. Br J Clin Pharmacol. 2020. PMID: 31912911. doi:10.1111/bcp.14211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。